Enveda secures $311M to bring more nature-derived AI drugs into clinical trials

Fecha de publicación: 23 de septiembre de 2026, 19:31

The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.